Dr. Maxwell Sauder

Dermatologist, Toronto, ON

Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School.

Dr. Sauder is currently an assistant professor at University of Toronto. He is an onco-dermatologist and fellowship director at Princess Margaret Cancer Centre. He also works at a private practice where he is the principle investigator on many clinical trials and the Pigmented Lesion Clinic director

2:40 PM - 3:10 PM

FRI Apr 19

Heads Up! A Topline Review of 52-Week Tildrakizumab Phase 3 Clinical Data in Scalp Psoriasis

Long-term data from Phase 3 clinical trials prospectively evaluating currently available biologics in the treatment of scalp psoriasis are limited. In this session, 52-week Phase 3 trial data for tildrakizumab, assessing efficacy and patient-reported outcomes in the treatment of moderate-to-severe psoriasis of the scalp, will be presented. To demonstrate how the trial data can translate into the real-world, a patient case will be shared. The session will conclude with an opportunity for the audience to pose questions.

Learning Objectives:
After attending this program, attendees will be able to:

  1. Recognize current unmet needs and challenges in the management of scalp psoriasis
  2. Apply phase 3 clinical trial data of IL-23 inhibitors in the treatment of scalp psoriasis to clinical practice
  3. Identify patients with scalp psoriasis for whom IL-23 inhibitor therapy is appropriate

11:25 AM - 11:55 AM

SAT Apr 20

Adjuvant Therapy of Melanoma: update 2024

Brief session description:
In this interactive session, we will review the actual staging classification for melanoma and underline high risk groups. Major innovations have recently been made in the management of high risk stage III patients with the use of immunotherapy and targeted therapy. Adjuvant anti-PD1 immunotherapy is now indicated in Stage IIB and IIC patients and recent data on these treatment options will be presented including the side effect profile.

Objectives:

  1. Understand the importance of Adjuvant therapy for High-risk melanoma
  2. Review Adjuvant treatment options for Stage III and present the role of immunotherapy in high-risk Stage II patients
  3. Emphasis the role of dermatologists in the diagnosis, counselling and follow-up of melanoma patients